《再生醫療法》於 2026 年 1 月 1 日正式施行，制度性延續《特管辦法》下已核定之再生醫療技術項目，確保病人安全和權益。長聖生技已與多家醫療機構合作，執行多項依特管辦法核准之再生醫療計畫，累積實際臨床應用經驗與真實世界數據（RWD），為再生醫療法架構下之制度承接與後續發展奠定基礎。
公司聚焦於治療危及生命或造成嚴重失能之重大疾病，與再生雙法推動方向一致，並以免疫細胞、幹細胞與外泌體為主要技術平台，持續開發多元再生醫療技術與再生醫療製劑，擴大現行醫療體系下的治療選項，並致力於改善病患生活品質。
The Regenerative Medicine Act came into effect on January 1, 2026, institutionally continuing regenerative medical technologies previously approved under the Regulations Governing Specific Medical Techniques (the “Special Approval Program”), thereby ensuring patient safety and protection of patient rights.
Ever supreme has long collaborated with multiple medical institutions to implement several regenerative medicine programs approved under the Special Approval Program, accumulating practical clinical experience and real-world data (RWD), which lay a solid foundation for regulatory transition and subsequent development under the framework of the Regenerative Medicine Act.
The Company focuses on the treatment of life-threatening or severely disabling diseases, in alignment with the policy objectives of the dual regenerative medicine laws. Leveraging its core technology platforms in immune cells, stem cells, and exosomes, Ever supreme continues to develop a diversified portfolio of regenerative medical technologies and regenerative medicine products, expanding treatment options within the current healthcare system and striving to improve patients’ quality of life.
| 再生技術項目 regenerative medical technologies |
期別 stage |
核准醫療機構 approved medical institutions |
|---|---|---|
| ADCV01 | 1-4期 stage 1-4 |
台大、國泰、台中慈濟、北港、安南 NTUH、CGH、TTZUCHI、CMUBH、TMANH |
| ADCV02 | 4期 stage 4 |
中附醫、新竹附醫、安南 CMUH、CMUHCH、TMANH |
| DC-CIK01 | 4期 stage 4 |
新竹附醫、亞大、安南 CMUHCH、AUH、TMANH |
| CIK | 1-3期 stage 1-3 |
彰化秀傳、彰濱秀傳 SCMH、CBSCMH |
| CIK | 血腫 hematoma |
中附醫、高醫 CMUH、KMUH |
| GDT | 4期 stage 4 |
中附醫、北榮、新竹附醫、亞大、光田、中港澄清、台中慈濟、安南、永康奇美、聯新 CMUH、TVGH、CMUHCH、AUH、KTGH、CCHCKB、TTZUCHI、TMANH、CMMC、TZUCHI |
| DC-CIK(WT1) | 4期 stage 4 |
新竹附醫、安南、聯新 CMUHCH、TMANH、TZUCHI |
| BM-MSC | 中附醫、中國醫藥大學附設醫院台北分院、新竹附醫、安南 CMUH、CMUH-Taipei、CMUHCH、TMANH |
■ 有關自體免疫或幹細胞治療相關資訊，歡迎來信長聖官方信箱： service@ever-supreme.com.tw
■ 或立即來電洽詢： 04-2325-2888